PURPOSE: To report the initial experience with endovascular aortic repair (EVAR) in patients with ruptured or symptomatic abdominal aortic aneurysms (AAA) and to compare the results with conventional open surgery. METHODS: Between May 1999 and December 2001, 24 patients (21 men; mean age 75 years, range 56-89) with ruptured or symptomatic AAA underwent EVAR using a specially designed aortomonoiliac endograft. Six patients were selected based on device and operator availability; the subsequent 18 patients were treated under a modified management protocol that offered stent-graft repair to all symptomatic AAA patients. The results of this new treatment protocol were analyzed on an intention-to-treat basis for the last 8 months of the study. The 30-day outcomes in all patients treated with emergency EVAR were compared with 40 consecutive, contemporaneous patients undergoing open surgery for symptomatic or ruptured AAA. RESULTS: No early conversions to open surgery were performed. Significantly decreased operative blood loss and intensive care stay (p<0.05 for both) were observed in EVAR patients. The mortality rate for EVAR patients was 17% compared to 32% in conventionally treated patients (NS). Among patients with ruptured AAA, the 30-day mortality rates were 24% (4/17) and 41% (12/29) for EVAR and open surgery, respectively (NS). Of 26 unselected patients who were treated prospectively under the modified protocol, the majority (81%, 21/26) had anatomy suitable for endovascular repair; however, only 18 (69%) underwent EVAR owing to a short infrarenal neck (n=2) or device/operator unavailability (n=6). CONCLUSIONS: EVAR is a feasible treatment in the majority of patients with ruptured or symptomatic AAA. The 30-day mortality appears to be similar between conventionally treated patients and those undergoing endovascular repair.
PURPOSE: To report the initial experience with endovascular aortic repair (EVAR) in patients with ruptured or symptomatic abdominal aortic aneurysms (AAA) and to compare the results with conventional open surgery. METHODS: Between May 1999 and December 2001, 24 patients (21 men; mean age 75 years, range 56-89) with ruptured or symptomatic AAA underwent EVAR using a specially designed aortomonoiliac endograft. Six patients were selected based on device and operator availability; the subsequent 18 patients were treated under a modified management protocol that offered stent-graft repair to all symptomatic AAA patients. The results of this new treatment protocol were analyzed on an intention-to-treat basis for the last 8 months of the study. The 30-day outcomes in all patients treated with emergency EVAR were compared with 40 consecutive, contemporaneous patients undergoing open surgery for symptomatic or ruptured AAA. RESULTS: No early conversions to open surgery were performed. Significantly decreased operative blood loss and intensive care stay (p<0.05 for both) were observed in EVAR patients. The mortality rate for EVAR patients was 17% compared to 32% in conventionally treated patients (NS). Among patients with ruptured AAA, the 30-day mortality rates were 24% (4/17) and 41% (12/29) for EVAR and open surgery, respectively (NS). Of 26 unselected patients who were treated prospectively under the modified protocol, the majority (81%, 21/26) had anatomy suitable for endovascular repair; however, only 18 (69%) underwent EVAR owing to a short infrarenal neck (n=2) or device/operator unavailability (n=6). CONCLUSIONS: EVAR is a feasible treatment in the majority of patients with ruptured or symptomatic AAA. The 30-day mortality appears to be similar between conventionally treated patients and those undergoing endovascular repair.
Authors: April E Nedeau; Frank B Pomposelli; Allen D Hamdan; Mark C Wyers; Richard Hsu; Teviah Sachs; Jeffrey J Siracuse; Mark L Schermerhorn Journal: J Vasc Surg Date: 2012-05-23 Impact factor: 4.268
Authors: Ilias Dalainas; Giovanni Nano; Paolo Bianchi; Silvia Stegher; Renato Casana; Giovanni Malacrida; Domenico G Tealdi Journal: World J Surg Date: 2006-10 Impact factor: 3.352
Authors: G Carrafiello; G Piffaretti; D Laganà; F Fontana; M Mangini; A M Ierardi; F Piacentino; A Canì; G Mariscalco; A Di Massa; S Cuffari; P Castelli; C Fugazzola Journal: Radiol Med Date: 2011-09-02 Impact factor: 3.469
Authors: Kristina A Giles; Allen D Hamdan; Frank B Pomposelli; Mark C Wyers; Suzanne E Dahlberg; Marc L Schermerhorn Journal: J Endovasc Ther Date: 2009-10 Impact factor: 3.487
Authors: Harald Teufelsbauer; Alexander M Prusa; Klaus Wolff; Mariana Sahal; Thomas Hölzenbein; Georg Kretschmer; Ihor Huk; Peter Polterauer Journal: Wien Klin Wochenschr Date: 2003-09-15 Impact factor: 1.704
Authors: Jelle W Raats; Hans C Flu; Gwan H Ho; Eelco J Veen; Louwerens D Vos; Ewout W Steyerberg; Lijckle van der Laan Journal: Clin Interv Aging Date: 2014-10-13 Impact factor: 4.458